CEBP CTRC-AACR San Antonio Breast Cancer Symposium Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Camoirano, A.
Right arrow Articles by De Flora, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Camoirano, A.
Right arrow Articles by De Flora, S.
Cancer Epidemiology Biomarkers & Prevention Vol. 10, 775-783, July 2001
© 2001 American Association for Cancer Research

Oltipraz Chemoprevention Trial in Qidong, People’s Republic of China

Results of Urine Genotoxicity Assays as Related to Smoking Habits1

Anna Camoirano, Maria Bagnasco, Carlo Bennicelli, Cristina Cartiglia, Jin-Bing Wang, Bao-Chu Zhang, Yuan-Rong Zhu, Geng-Sun Qian, Patricia A. Egner, Lisa P. Jacobson, Thomas W. Kensler and Silvio De Flora2

Department of Health Sciences, University of Genoa, I-16132 Genoa, Italy [A. C., M. B., C. B., C. C., S. D. F.]; Qidong Liver Cancer Institute, Qidong, Jiangsu Province, 226200 People’s Republic of China [J-B. W., B-C. Z., Y-R. Z.]; Shanghai Cancer Institute, Shanghai, 200032 People’s Republic of China [G-S. Q.]; and The Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland 21205 [P. A. E., L. P. J., T. W. K.]

A Phase II chemoprevention trial was carried out in Qidong, Jiangsu Province, People’s Republic of China. The recruited subjects, all of whom were positive for serum aflatoxin-albumin adducts, were divided into three treatment arms: placebo; oltipraz ([5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione]) given daily at 125 mg p.o.; and oltipraz given once per week at 500 mg p.o. Besides biomarkers related to aflatoxin B1 exposure, the genotoxicity of blind-coded urine XAD-2 concentrates was evaluated in 201 subjects on the fifth and seventh week of intervention. Genotoxicity was assessed both in the Ames reversion test in strain YG1024 of Salmonella typhimurium, in the presence of an exogenous metabolic system (S9 mix), with or without ß-glucuronidase, and in a DNA repair test in Escherichia coli. Heating of concentrated urine samples or of cigarette smoke condensates was discovered to result in a significant enhancement of their mutagenicity. It was also found that the mutagenicity of condensates from the most extensively used brands of cigarettes in Qidong was much lower than that of Western cigarette brands. Urine mutagenicity was unrelated to treatment with oltipraz, intervention time, gender, and supplement of S9 mix with ß-glucuronidase. Mutagenicity was significantly but variably higher in cigarette smokers than in nonsmokers, which suggests that the urinary excretion of mutagens in the examined population was not exclusively attributable to smoking. Nevertheless, within smokers (28% of the recruited subjects; 67% of all males), the mutagenic potency was significantly correlated with the self-reported number of cigarettes smoked per day and, even more sharply, with the cotinine concentrations in urines. In conclusion, this study demonstrated the validity of urine mutagenicity assays as a biomarker of tobacco smoke exposure that can be investigated on a relatively large scale in chemoprevention trials and provided evidence that oltipraz treatment had no influence on this parameter in the examined population.




This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. J. Kelley, E. M. Glaser, J. E. Herndon II, F. Becker, R. Bhagat, Y.-J. Zhang, R. M. Santella, S. G. Carmella, S. S. Hecht, L. Gallot, et al.
Safety and Efficacy of Weekly Oral Oltipraz in Chronic Smokers
Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 892 - 899.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. Zhang and G. B. Gordon
A strategy for cancer prevention: Stimulation of the Nrf2-ARE signaling pathway
Mol. Cancer Ther., July 1, 2004; 3(7): 885 - 893.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. Begleiter, K. Sivananthan, T. J. Curphey, and R. P. Bird
Induction of NAD(P)H Quinone: Oxidoreductase1 Inhibits Carcinogen-induced Aberrant Crypt Foci in Colons of Sprague-Dawley Rats
Cancer Epidemiol. Biomarkers Prev., June 1, 2003; 12(6): 566 - 572.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.